The coding microsatellite mutation profile of PMS2-deficient colorectal cancer.
Aged
Colorectal Neoplasms
/ complications
Colorectal Neoplasms, Hereditary Nonpolyposis
/ complications
DNA Mismatch Repair
/ genetics
DNA-Binding Proteins
/ genetics
Female
Germ-Line Mutation
/ genetics
Humans
Male
Microsatellite Instability
Microsatellite Repeats
/ genetics
Middle Aged
Mismatch Repair Endonuclease PMS2
/ genetics
MutL Protein Homolog 1
/ genetics
MutS Homolog 2 Protein
/ genetics
HNPCC
Hereditary colorectal cancer
Immunology of cancer
Molecular pathways
Journal
Experimental and molecular pathology
ISSN: 1096-0945
Titre abrégé: Exp Mol Pathol
Pays: Netherlands
ID NLM: 0370711
Informations de publication
Date de publication:
10 2021
10 2021
Historique:
received:
09
06
2021
accepted:
19
07
2021
pubmed:
25
7
2021
medline:
24
12
2021
entrez:
24
7
2021
Statut:
ppublish
Résumé
Lynch syndrome (LS) is caused by a pathogenic heterozygous germline variant in one of the DNA mismatch repair (MMR) genes: MLH1, MSH2, MSH6 or PMS2. LS-associated colorectal carcinomas (CRCs) are characterized by MMR deficiency and by accumulation of multiple insertions/deletions at coding microsatellites (cMS). MMR deficiency-induced variants at defined cMS loci have a driver function and promote tumorigenesis. Notably, PMS2 variant carriers face only a slightly increased risk of developing CRC. Here, we investigate whether this lower penetrance is also reflected by differences in molecular features and cMS variant patterns. Tumor DNA was extracted from formalin-fixed paraffin-embedded (FFPE) tissue cores or sections (n = 90). Tumors originated from genetically proven germline pathogenic MMR variant carriers (including 14 PMS2-deficient tumors). The mutational spectrum was analyzed using fluorescently labeled primers specific for 18 cMS previously described as mutational targets in MMR-deficient tumors. Immune cell infiltration was analyzed by immunohistochemical detection of T-cells on FFPE tissue sections. The cMS spectrum of PMS2-deficient CRCs did not show any significant differences from MLH1/MSH2-deficient CRCs. PMS2-deficient tumors, however, displayed lower CD3-positive T-cell infiltration compared to other MMR-deficient cancers (28.00 vs. 55.00 per 0.1 mm
Identifiants
pubmed: 34302852
pii: S0014-4800(21)00067-8
doi: 10.1016/j.yexmp.2021.104668
pii:
doi:
Substances chimiques
DNA-Binding Proteins
0
G-T mismatch-binding protein
0
PMS2 protein, human
EC 3.6.1.-
MSH2 protein, human
EC 3.6.1.3
Mismatch Repair Endonuclease PMS2
EC 3.6.1.3
MutL Protein Homolog 1
EC 3.6.1.3
MutS Homolog 2 Protein
EC 3.6.1.3
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
104668Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.